Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure
NCT01823393 · University Hospital, Montpellier · PHASE4 · terminated · last registry update 2026-06-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Difficulty of inclusion” | – | Registry record, University Hospital, Montpellier |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SERPINC1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Phase 3 first posted: China National Center for Cardiovascular Diseases, Alteplase + Standard Anticoagulation (NCT07917078)
- 2026-10-28Also stopped (terminated): Consorci Sanitari de l'Alt Penedès i Garraf, Low dose heparin + Normal saline (NCT05209841)
- 2026-10-26Also stopped (terminated): Ottawa Hospital Research Institute, a drug against SERPINC1 (NCT03148912)
- 2026-10-22Also stopped (terminated): Oslo University Hospital, Floxuridine (NCT04898504)
- 2026-10-09Results posted on the registry: Beth Israel Deaconess Medical Center, Enoxaparin + Enoxaparin + Rosuvastatin (NCT03532139)
- 2026-09-17Also stopped (withdrawn): H. Lee Moffitt Cancer Center and Research Institute, a drug against SERPINC1 (NCT05041335)
- 2026-09-01Phase 3 first posted: General University Hospital, Prague, Vaginal Micronized Progesterone (Progesterone Besins) + Enoxaparin (Clexane) (NCT07796737)
- 2026-08-18Results posted on the registry: Penumbra Inc., Anticoagulation (NCT05684796)
- 2026-07-15Also stopped (withdrawn): Wake Forest University Health Sciences, a drug against SERPINC1 (NCT06013449)
- 2026-06-25Results posted on the registry: OHSU Knight Cancer Institute, Dexamethasone + Floxuridine (NCT04251715)
- 2026-06-25Also stopped (terminated): OHSU Knight Cancer Institute, Dexamethasone + Floxuridine (NCT04251715)
- 2026-06-24Results posted on the registry: SHI Jia, Prothrombin Complex Concentrate, Human + Fresh Frozen Plasma (NCT04244981)
- 2026-06-24Also stopped (terminated): SHI Jia, Prothrombin Complex Concentrate, Human + Fresh Frozen Plasma (NCT04244981)
- 2026-06-08Results posted on the registry: Weill Medical College of Cornell University, Melphalan + Carboplatin (NCT04994977)
- 2026-06-08Also stopped (terminated): Weill Medical College of Cornell University, Melphalan + Carboplatin (NCT04994977)
- 2026-05-28Results posted on the registry: Riad Rahhal, Sodium bicarb lock (NCT05813535)
- 2026-04-20Also stopped (withdrawn): ExThera Medical Corporation, a drug against SERPINC1 (NCT06637800)
- 2026-04-17Also stopped (terminated): Anthos Therapeutics, Inc., Abelacimab + Dalteparin (NCT05171075)
- 2026-04-06Also stopped (withdrawn): Assistance Publique - Hôpitaux de Paris, Plaquenil 200Mg Tablet + Placebo oral tablet (NCT04275778)
- 2026-04-01Results posted on the registry: Jocelyn Fitzgerald, Multimodal Bundle Drugs + Bladder Instillation (NCT05658874)
- 2026-04-01Also stopped (terminated): Jocelyn Fitzgerald, Multimodal Bundle Drugs + Bladder Instillation (NCT05658874)
- 2026-03-02Results posted on the registry: Regeneron Pharmaceuticals, REGN7508 + Enoxaparin (NCT06454630)
- 2026-02-23Also stopped (terminated): Anthos Therapeutics, Inc., Abelacimab + Apixaban (NCT05171049)
- 2026-02-03Results posted on the registry: Urigen, URG101 + Placebo (NCT02591199)
- 2026-02-03Also stopped (terminated): Urigen, URG101 + Placebo (NCT02591199)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision